Second Half Financial Partners LLC Invests $3.45 Million in Johnson & Johnson (NYSE:JNJ)

Second Half Financial Partners LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 21,310 shares of the company’s stock, valued at approximately $3,454,000. Johnson & Johnson accounts for approximately 1.8% of Second Half Financial Partners LLC’s portfolio, making the stock its 13th biggest position.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Johnson & Johnson in the third quarter worth approximately $72,049,000. Vance Wealth Inc. boosted its holdings in Johnson & Johnson by 1.2% in the 3rd quarter. Vance Wealth Inc. now owns 19,188 shares of the company’s stock worth $3,110,000 after buying an additional 227 shares during the period. Beddow Capital Management Inc. increased its stake in Johnson & Johnson by 2.6% in the 3rd quarter. Beddow Capital Management Inc. now owns 51,830 shares of the company’s stock worth $8,400,000 after buying an additional 1,290 shares in the last quarter. First City Capital Management Inc. raised its holdings in Johnson & Johnson by 8.5% during the third quarter. First City Capital Management Inc. now owns 11,003 shares of the company’s stock valued at $1,783,000 after acquiring an additional 858 shares during the period. Finally, Fifth Third Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 13.5% in the third quarter. Fifth Third Wealth Advisors LLC now owns 19,775 shares of the company’s stock valued at $3,205,000 after acquiring an additional 2,350 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 22.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on JNJ shares. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Royal Bank of Canada raised their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Finally, Citigroup increased their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $175.94.

Johnson & Johnson Stock Down 1.2 %

Shares of JNJ stock opened at $152.97 on Wednesday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The firm has a market capitalization of $368.29 billion, a PE ratio of 22.14, a P/E/G ratio of 2.74 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock’s 50-day simple moving average is $160.83 and its 200-day simple moving average is $156.19.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.66 earnings per share. Equities analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.